Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"TrueBinding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TrueBinding Announces Results of TB006 Phase 1b\/2 Placebo Controlled Proof-of-Concept Trial Showing Improvement on the Primary Cognition and Function Endpoint in Patients with Mild to Severe Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"TrueBinding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TrueBinding Granted Type B End-of-Phase 2 Meeting with FDA for Discussion of Accelerated Development Pathway for TB006 Alzheimer's Disease Treatment","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"TrueBinding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Open-Label Extension Study for Alzheimer's Treatment Showed Disease Reversal in Nearly Half of Study Participants in Just Three Months","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by TrueBinding

    Menu

    TrueBinding

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              TrueBinding

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Open-Label Extension Study for Alzheimer's Treatment Showed Disease Reversal in Nearly Half of Study Participants in Just Three Months

              Details:

              TB006 is a humanized monoclonal antibody that, by blocking Galectin-3, the root cause of neuroinflammation and aggregation of Aβ and pTau and other pathogenic factors, has the potential to improve cognition and functioning of patients with alzheimer's disease (AD).

              Lead Product(s): TB006

              Therapeutic Area: Neurology Product Name: TB006

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 28, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              TrueBinding

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              TrueBinding Granted Type B End-of-Phase 2 Meeting with FDA for Discussion of Accelerated Development Pathway for TB006 Alzheimer's Disease Treatment

              Details:

              TB006 is a humanized monoclonal antibody that, by blocking Galectin-3, the root cause of neuroinflammation and aggregation of Aβ and pTau and other pathogenic factors, has the potential to improve cognition and functioning of patients with alzheimer's disease (AD).

              Lead Product(s): TB006

              Therapeutic Area: Neurology Product Name: TB006

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 14, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              TrueBinding

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              TrueBinding Announces Results of TB006 Phase 1b/2 Placebo Controlled Proof-of-Concept Trial Showing Improvement on the Primary Cognition and Function Endpoint in Patients w...

              Details:

              TB006 is a humanized monoclonal antibody that, based on preclinical data and early clinical studies, has the potential to improve cognition and functioning of patients with Alzheimer’s disease (AD).

              Lead Product(s): TB006

              Therapeutic Area: Neurology Product Name: TB006

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 18, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY